Lord Hunt of Kings Heath

UK Biobank is a charity and operationally independent of government. The Government has been working closely with UK Biobank in its response to the data breach which it reported to the Government on 20 April 2026. Measures taken so far have included the suspension of access to their research analysis platform, revocation of access permissions from the institutions involved, rapid removal of the listings from the e-commerce platform, self‑referral to the Information Commissioners Office, and urgent work to introduce technical barriers to prevent download of participant‑level data.

UK Biobank is a charity and operationally independent of government. The Government has been working closely with UK Biobank in its response to the data breach which it reported to the Government on 20 April 2026. Measures taken so far have included the suspension of access to their research analysis platform, revocation of access permissions from the institutions involved, rapid removal of the listings from the e-commerce platform, self‑referral to the Information Commissioners Office, and urgent work to introduce technical barriers to prevent download of participant‑level data.

UK Biobank is a charity and operationally independent of government. The Government has been working closely with UK Biobank in its response to the data breach which it reported to the Government on 20 April 2026. Measures taken so far have included the suspension of access to their research analysis platform, revocation of access permissions from the institutions involved, rapid removal of the listings from the e-commerce platform, self‑referral to the Information Commissioners Office, and urgent work to introduce technical barriers to prevent download of participant‑level data.

UK Biobank is a charity and operationally independent of government. The Government has been working closely with UK Biobank in its response to the data breach which it reported to the Government on 20 April 2026. Measures taken so far have included the suspension of access to their research analysis platform, revocation of access permissions from the institutions involved, rapid removal of the listings from the e-commerce platform, self‑referral to the Information Commissioners Office, and urgent work to introduce technical barriers to prevent download of participant‑level data.

UK Biobank is a charity and operationally independent of government. The Government has been working closely with UK Biobank in its response to the data breach which it reported to the Government on 20 April 2026. Measures taken so far have included the suspension of access to their research analysis platform, revocation of access permissions from the institutions involved, rapid removal of the listings from the e-commerce platform, self‑referral to the Information Commissioners Office, and urgent work to introduce technical barriers to prevent download of participant‑level data.

In 2025/26, funding for the core community pharmacy contractual framework was increased to £3.1 billion. This represented the largest uplift in funding of any part of the National Health Service at the time, at over 19% across 2024/25 and 2025/26.

The Department is currently consulting with Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27.

When the market price of a medicine suddenly increases, pharmacy contractors can request an increase to the reimbursement price, known as a concessionary price, from the Department via Community Pharmacy England. ‘Real-time’ data from suppliers, both wholesalers and manufacturers, obtained under Regulation 27 of The Health Service Products (Provision and Disclosure of Information) Regulations 2018 is used to set the concessionary price. This ensures that prices set are reflective of current market prices and availability, with the aim of mitigating pharmacy contractors dispensing at a loss when market prices suddenly rise.

Pharmacy contractors are reimbursed for medical devices in line with the listed prices on Part IX of the NHS Drug Tariff. Suppliers should adhere to these prices as per the terms of their listing.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

To help ensure every National Health Service hospital in England can benefit from digital transformation, the Government has invested £1.9 billion in either new or existing electronic patient record (EPR) systems. This has resulted in almost all trusts now having an EPR in place, or in delivery. Evidence from secondary care shows that EPRs are contributing to a 4.5% reduction in length of stay and a 13% lower cost in admitted patient spells.

Whilst this represents significant progress, we are continuing to fully realise the benefits of EPRs by building skills and changing management capacity. This includes sharing best practice, improving usability, training users more effectively, and ensuring systems are tailored to local context rather than adopting a one size fits all approach.

To help ensure every National Health Service hospital in England can benefit from digital transformation, the Government has invested £1.9 billion in either new or existing electronic patient record (EPR) systems. This has resulted in almost all trusts now having an EPR in place, or in delivery. Evidence from secondary care shows that EPRs are contributing to a 4.5% reduction in length of stay and a 13% lower cost in admitted patient spells.

Whilst this represents significant progress, we are continuing to fully realise the benefits of EPRs by building skills and changing management capacity. This includes sharing best practice, improving usability, training users more effectively, and ensuring systems are tailored to local context rather than adopting a one size fits all approach.

The Government recognises how important it is that patients with rare diseases can benefit from access to effective new medicines.

The National Institute for Health and Care Excellence (NICE) is able to recommend the vast majority of medicines it evaluates for use in the National Health Service, including medicines for the treatment of rare diseases. The recently announced increase to the cost-effectiveness threshold will, alongside measures announced in the Life Sciences Sector Plan, increase both the speed and breadth of patient access to innovative medicines.

Data from the National Institute for Health and Care Excellence shows that between 2021/22 and 2025/26, the total number of appraisals that were terminated was 100. Over the past five years, 41% of terminated appraisals related to rare disease medicines.

The Government recognises the challenges faced by heart and lung transplant services, as highlighted in the BBC File on 4 Investigates programme. Clinical teams have continued to improve activity and patient outcomes, reflecting their expertise and commitment. However, challenges remain and further work is needed to address variation in access, workforce pressures, and the complexity of organ acceptance and allocation.

NHS England is working closely with the Department, NHS Blood and Transplant (NHSBT), and transplant centres to address these issues. The concerns raised in the programme are consistent with challenges previously identified by the Organ Utilisation Group and explored through the Implementation Steering Group for Organ Utilisation’s Cardiothoracic Information Collation Exercise. This has informed NHS England’s clinically led national improvement programme for heart and lung transplant services, which brings together clinicians, patients, and patient organisations to co-design solutions to improve services in these key areas.

In parallel, NHSBT is delivering a Department funded programme of Assessment and Recovery Centres (ARC), including lung ARC pilot schemes launched in February 2026, to improve the preservation and utilisation of donor organs for transplantation.

While it is encouraging that activity has increased and waiting lists have reduced, the Government recognises that continued work is needed to ensure services are consistently accessible and resilient. Work will continue with patients, partners, and local centres to ensure care is personalised, equitable, and sustainable, and to address challenges facing the transplant workforce.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

The report will be considered as part of the wider work underway on future engagement models.

The removal of councils of governors from National Health Service foundation trusts forms part of the wider 10-Year Health Plan’s aim to ensure hospitals put patient experiences and outcomes at the heart of their decision-making.

While governors have provided helpful advice and oversight for some foundation trusts, we now need to move to a more dynamic model, drawing on patient, staff, and stakeholder insight.

Research is crucial in tackling cancer, which is why the Department invests over £1.7 billion per year in research through the National Institute for Health and Care Research (NIHR).

In December 2025, the NIHR announced an initial £13.7 million investment in the Brain Tumour Research Consortium. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the consortium through funding of work packages. This brings the total investment to over £25 million.

The exact amount paid as of March 2026 is £50,000, which was paid to the contractor on 31 December 2025. This payment was made to support start up activities for the consortium. The NIHR does not currently hold up-to-date expenditure, or a detailed breakdown of how this funding has been spent. This information is currently held by the research team of the NIHR Brain Tumour Research Consortium and will be provided to the NIHR in the future as part of the project’s annual financial returns.

For all awards, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.

Future payments will be issued over the period of the award contracts which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the consortium.

Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible. Oversight of the Brain Tumour Research Consortium is the responsibility of the NIHR.

In addition, the NIHR continues to strongly encourages brain cancer research applications through its regular funding opportunities.

Research is crucial in tackling cancer, which is why the Department invests over £1.7 billion per year in research through the National Institute for Health and Care Research (NIHR).

In December 2025, the NIHR announced an initial £13.7 million investment in the Brain Tumour Research Consortium. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the consortium through funding of work packages. This brings the total investment to over £25 million.

The exact amount paid as of March 2026 is £50,000, which was paid to the contractor on 31 December 2025. This payment was made to support start up activities for the consortium. The NIHR does not currently hold up-to-date expenditure, or a detailed breakdown of how this funding has been spent. This information is currently held by the research team of the NIHR Brain Tumour Research Consortium and will be provided to the NIHR in the future as part of the project’s annual financial returns.

For all awards, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.

Future payments will be issued over the period of the award contracts which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the consortium.

Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible. Oversight of the Brain Tumour Research Consortium is the responsibility of the NIHR.

In addition, the NIHR continues to strongly encourages brain cancer research applications through its regular funding opportunities.

Research is crucial in tackling cancer, which is why the Department invests over £1.7 billion per year in research through the National Institute for Health and Care Research (NIHR).

In December 2025, the NIHR announced an initial £13.7 million investment in the Brain Tumour Research Consortium. In January 2026, the NIHR announced further investment of a minimum of £11.7 million in the consortium through funding of work packages. This brings the total investment to over £25 million.

The exact amount paid as of March 2026 is £50,000, which was paid to the contractor on 31 December 2025. This payment was made to support start up activities for the consortium. The NIHR does not currently hold up-to-date expenditure, or a detailed breakdown of how this funding has been spent. This information is currently held by the research team of the NIHR Brain Tumour Research Consortium and will be provided to the NIHR in the future as part of the project’s annual financial returns.

For all awards, contracting and further payments are contingent upon teams submitting and reviewing detailed costs and, if applicable, agreeing to the suggested amendments and requests for clarification which are currently in progress.

Future payments will be issued over the period of the award contracts which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the consortium.

Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible. Oversight of the Brain Tumour Research Consortium is the responsibility of the NIHR.

In addition, the NIHR continues to strongly encourages brain cancer research applications through its regular funding opportunities.

NHS England’s policy guidance and prescribing advice on liothyronine reflects the National Institute for Health and Care Excellence’s recommendations and the evidence on liothyronine. That guidance recommends that liothyronine should not be routinely prescribed, because it is not clinically or cost-effective, but sets out the exceptions where it may be an appropriate consideration for prescribers.

NHS England expects commissioners and prescribers to have due regard to its guidance. While integrated care boards may determine their own implementation arrangements, as part of the new operating model, regions will oversee commissioner and provider performance, including access to high quality care and the reduction of health inequalities.

NHS England’s policy guidance and prescribing advice on liothyronine reflects the National Institute for Health and Care Excellence’s recommendations and the evidence on liothyronine. That guidance recommends that liothyronine should not be routinely prescribed, because it is not clinically or cost-effective, but sets out the exceptions where it may be an appropriate consideration for prescribers.

NHS England expects commissioners and prescribers to have due regard to its guidance. While integrated care boards may determine their own implementation arrangements, as part of the new operating model, regions will oversee commissioner and provider performance, including access to high quality care and the reduction of health inequalities.

Integrated care boards (ICBs) are responsible for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population. Therefore, responses to these questions should be requested directly from the North East and North Cumbria ICB.

Integrated care boards (ICBs) are responsible for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population. Therefore, responses to these questions should be requested directly from the North East and North Cumbria ICB.

Integrated care boards (ICBs) are responsible for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population. Therefore, responses to these questions should be requested directly from the North East and North Cumbria ICB.

The following table shows the total number of general dental practice contracts, including the number of units of dental activity (UDA) and the total value, that were handed back in the North East and North Cumbria Integrated Care Board since it took over the delegated commissioning responsibility in April 2023:

Integrated care boards (ICBs) are responsible for commissioning primary care services, including National Health Service dentistry, to meet the needs of the local population. The North East and North Cumbria ICB has implemented measures to improve access to dental services as part of the ICB’s Oral Health and Dental Strategy for 2025/27. Further information can be found on the NHS.UK website, in an online format.

The Government is committed to ensuring that people can access urgent dental care when they need it. Over the past year, ICBs have been commissioning additional urgent dental appointments and there is now an urgent care safety net available in all areas of the country. 1.8 million additional courses of NHS dental treatment have been delivered in the seven months between April to October 2025 compared to the corresponding months prior to the general election.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.

NHS England’s published enforcement guidance sets out how it uses its enforcement powers and the regulatory and statutory processes in the event of enforcement action. The guidance states that directions under section 14Z61 should only be issued as a last resort where voluntary action has not proved possible and NHS England must be satisfied that the integrated care board is failing or has failed to discharge its functions, or that there is a significant risk it will do so.